BCTX - Briacell trading halted on news pending
After a gain of ~5.2% in the early hours, the trading of BriaCell Therapeutics (BCTX) shares remains halted for more than an hour pending the release of material news.Yesterday, BriaCell almost doubled in value after announcing an update to overall survival ((OS)) data in advanced breast cancer patients.The patients (n=7) treated with its lead candidate Bria-IMT in combination with checkpoint inhibitors, including pembrolizumab (KEYTRUDA) demonstrated 12.0 months average overall survival benefit.That was better than the 7.2-9.8 months survival in historical comparison treatment trials.In patients with Grade I/II tumors and those with 2+ HLA matches, the average overall survival stood at 12.5 months and 13.4 months, the company said.In April, BriaCell announced data for Bria-IMT alone or in combination with pembrolizumab and Incyte’s retifanlimab in patients with advanced breast cancer.
For further details see:
Briacell trading halted on news pending